Please login to the form below

Not currently logged in
Email:
Password:

Coreg CR study knocks a quarter off Flamelís shares

Shares in French drug delivery company Flamel Technologies fell by a quarter at the end of last week after a study of its daily controlled-release heart disease drug, Coreg CR, failed demonstrate augmented efficacy when compared with an existing twice-daily treatment, Coreg IR.

Shares in French drug delivery company Flamel Technologies fell by a quarter at the end of last week after a study of its daily controlled-release heart disease drug, Coreg CR, failed demonstrate augmented efficacy when compared with an existing twice-daily treatment, Coreg IR.

The results of the study were published in the Journal of Cardiac Failure.

As a result, Flamelís shares dropped a massive 24.6 per cent (USD 3.12) to settle at USD 9.56. The stock reached a 52-week low of USD 8.96 during the regular trading session.

Coreg IR is sold by GlaxoSmithKline (GSK) in the US, but it is currently experiencing generic competition from Israeli-headquartered Teva and US-based Mylan. Coreg CR was approved by the FDA in October 2006.

Merriman Curhan Ford analysts believe that formulary adoption of Coreg CR will be hindered in the near-term, limiting potential growth of prescriptions. They reaffirmed a "Neutral" rating to Flamel.

Flamel Technologies manufactures Coreg microparticles for GSK under a license agreement. Flamel's drug delivery technology is designed to control absorption of Coreg in the body.

28th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics